The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

Persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) under current antiviral therapy is a major barrier to eradication of chronic hepatitis B (CHB). Curing CHB will require novel strategies for specific disruption of cccDNA. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is a newly developed tool for site-specific cleavage of DNA targets directed by a synthetic guide RNA (gRNA) base-paired to the target DNA sequence. To examine whether this system can cleave HBV genomes, we designed eight gRNAs against HBV of genotype A. With the HBV-specific gRNAs, the CRISPR/Cas9 system significantly reduced the production of HBV core and surface proteins in Huh-7 cells transfected with an HBV-expression vector. Among eight screened gRNAs, two effective ones were identified. Interestingly, one gRNA targeting the conserved HBV sequence acted against different genotypes. Using a hydrodynamics-HBV persistence mouse model, we further demonstrated that this system could cleave the intrahepatic HBV genome-containing plasmid and facilitate its clearance in vivo, resulting in reduction of serum surface antigen levels. These data suggest that the CRISPR/Cas9 system could disrupt the HBV-expressing templates both in vitro and in vivo, indicating its potential in eradicating persistent HBV infection.

[1]  I. Katic,et al.  Targeted Heritable Mutation and Gene Conversion by Cas9-CRISPR in Caenorhabditis elegans , 2013, Genetics.

[2]  F. Căruntu,et al.  CccDNA persistence during natural evolution of chronic VHB infection. , 2005, Romanian journal of gastroenterology.

[3]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[4]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[5]  Yoshio Koyanagi,et al.  Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus , 2013, Scientific Reports.

[6]  Qihan Li,et al.  High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases , 2014, PLoS pathogens.

[7]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[8]  Daniel Stone,et al.  Predictors of Hepatitis B Cure Using Gene Therapy to Deliver DNA Cleavage Enzymes: A Mathematical Modeling Approach , 2013, PLoS Comput. Biol..

[9]  G. Stormo,et al.  Program in Gene Function and Expression Publications and Presentations Program in Gene Function and Expression 1-8-2013 Using defined finger-finger interfaces as units of assembly for constructing zinc-finger nucleases , 2014 .

[10]  V. Wong,et al.  Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. , 2005, Gastroenterology.

[11]  H. Blum,et al.  Generation of Covalently Closed Circular DNA of Hepatitis B Viruses via Intracellular Recycling Is Regulated in a Virus Specific Manner , 2010, PLoS pathogens.

[12]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[13]  Jeffrey C. Miller,et al.  A rapid and general assay for monitoring endogenous gene modification. , 2010, Methods in molecular biology.

[14]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[15]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[16]  H. Deveau,et al.  CRISPR/Cas system and its role in phage-bacteria interactions. , 2010, Annual review of microbiology.

[17]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[18]  A. McCaffrey,et al.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Y. Ono,et al.  Tbe complete nudeotide sequences of the cloned hepatitis B vims DNA; subtype adr and adw , 1983 .

[20]  R. Barrangou,et al.  CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. , 2011, Annual review of genetics.

[21]  Stan J. J. Brouns,et al.  Evolution and classification of the CRISPR–Cas systems , 2011, Nature Reviews Microbiology.

[22]  Zhenghong Yuan,et al.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  W. Mason,et al.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.

[24]  Ding‐Shinn Chen,et al.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection , 2006, Proceedings of the National Academy of Sciences.

[25]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[26]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Colby G Starker,et al.  In vivo Genome Editing Using High Efficiency TALENs , 2012, Nature.

[28]  Kai Li,et al.  Biological and Biomedical Applications of Engineered Nucleases , 2013, Molecular Biotechnology.

[29]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[30]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[31]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[32]  B. Hirt.  Selective extraction of polyoma DNA from infected mouse cell cultures. , 1967, Journal of molecular biology.

[33]  George M. Church,et al.  Heritable genome editing in C. elegans via a CRISPR-Cas9 system , 2013, Nature Methods.

[34]  H. Will,et al.  Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir In vitro do not lead to reduction of the closed circular DNA , 2000, Hepatology.

[35]  Jin-Soo Kim,et al.  Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases , 2014, Genome research.

[36]  Jeffry D. Sander,et al.  Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.

[37]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[38]  R. Sun,et al.  Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. , 2013, Gastroenterology.

[39]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.